Form 4: Amgen Director Michael V. Drake Receives 809 Shares Through RSU Grant

Amgen Inc. Director Michael V. Drake has acquired 809 shares of common stock through a Restricted Stock Unit (RSU) grant, increasing his beneficial ownership to 4,546.5983 shares.

Summary

• Amgen Inc. Director Michael V. Drake acquired 809 shares of common stock on May 23, 2025.
• The shares were acquired at a price of $0 per share.
• This transaction was a grant of Restricted Stock Units (RSUs) under the Amgen Inc. 2009 Director Incentive Program, which vested immediately.
• Vested RSUs are paid in shares of the company's common stock on a one-to-one basis, with directors having the option to defer payment.
• The acquired shares include 196 Dividend Equivalents (DEs) granted under the Director Program, subject to a qualifying dividend reinvestment plan.
• Following this transaction, Dr. Drake beneficially owns a total of 4,546.5983 shares of Amgen common stock.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a standard, expected compensation event for a director, aligning their interests with shareholders. It does not indicate any negative operational or financial issues for the company.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Michael V. Drake aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The immediate vesting of the RSUs provides a clear and direct benefit to the director, reflecting a commitment to retaining experienced board members.

Negatives

• The issuance of new shares, even for compensation, results in a minor dilution of existing shareholder equity, though the impact from this specific transaction is negligible.

Risks

• No specific risks are detailed in this Form 4 filing beyond the inherent risks associated with equity-based compensation and potential minor dilution.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This transaction is a routine insider compensation event within the biotechnology and pharmaceutical industry, where equity-based awards are a common component of executive and director remuneration. It does not reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• Equity-based compensation, such as Restricted Stock Units (RSUs), is a standard practice for compensating directors and executives across the biotechnology and pharmaceutical sectors, including major players like Pfizer, Johnson & Johnson, and Merck. The structure of Amgen's 2009 Director Incentive Program is consistent with typical industry compensation frameworks designed to align director interests with long-term shareholder value.
• The immediate vesting of RSUs for directors is also a common feature in some compensation plans, though others may include multi-year vesting schedules. The inclusion of Dividend Equivalents (DEs) is a standard mechanism to ensure that deferred equity awards accrue value equivalent to dividends paid on common stock.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Director Michael V. Drake from Amgen Inc. constitutes a related party transaction, as it involves a company director receiving compensation in the form of company stock. This is a standard and disclosed practice under the company's incentive programs.

Stakeholder Impact

• Shareholders: Minor, negligible dilution due to the issuance of shares for compensation. The alignment of director interests with shareholders through equity ownership is generally positive.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Amgen, AMGN, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSU grant, director compensation, equity incentive plan, beneficial ownership, biotechnology, pharmaceuticals